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Recommendations to travellers regarding yellow fever vac-
cination (YFV) are based on personal risk, previous vaccin-
ations, health status of the traveller and border regulations.
Recently, WHO extended the recommendation regarding
protection after YFV from 10 years to lifelong. We present
the results of a survey among Swiss tropical and travel
medicine experts, in which they were asked to decide upon
the correct vaccination approach in eight case scenarios.
YFV is one of the most often administered vaccines in
travel medicine [1] (40,000 doses per year in Switzerland
[personal communication]). With over 600 million admin-
istered doses worldwide, only 12 yellow fever (YF) cases
have been described in vaccinated persons [2]. Generally,
YFV is well tolerated, but severe reactions, such as yellow
fever vaccination-associated viscerotropic disease (YEL-
AVD) or yellow fever vaccination-associated neurotropic
disease (YEL-AND) occur in around 0.5/100,000 distrib-
uted doses [3]. In order to assess and harmonise indications
for yellow fever vaccination, a survey was performed dur-
ing a meeting of The Swiss Society of Tropical and Travel
Medicine in January 2014. Experts assessed eight real and
imaginary cases of travellers on whether YFV should be
given, not given, or if a written exemption should be is-
sued. Only one answer was possible and delay or cancella-
tion of the trip was not an option.
Physicians were asked to give a recommendation for two
scenarios: (i.) sufficient vaccine doses available and (ii.)
shortage of YFV, as this was a problem at that time.
Overall, 55 questionnaires were distributed, and 43 (78%)
were returned. Case descriptions, survey results and the
correct options according to Swiss vaccination recom-
mendations (version October 2013 [4]) are summarised in
table 1.
Cases in detail
1. + 2. There is no risk of YF infection for wife and hus-
band. For the wife's transit, no vaccination or ex-
emption is necessary. The husband needs YFV or
an exemption certificate, depending on the avail-
ability of YFV.
Independent of YFV availability, 60% of the spe-
cialists decided not to immunise the wife. More
than 35% favoured an exemption in case of vac-
cine shortage or would have vaccinated. In case of
vaccination, the wife would have been exposed to
an unnecessary risk, especially, as persons aged 60
years and above have an increased risk of YEL-
AVD [5]. For the husband, almost 90% opted for
vaccination in scenario (i.) and around 70% for an
exemption in scenario (ii.), i.e., a majority chose
the correct answer according to current recom-
mendations.
3. During pregnancy, YFV is generally not recom-
mended although teratogenic effects have not been
described [6]. The decision on vaccination during
pregnancy has to be taken after an individual risk/
benefit assessment [7]. As São Paulo and Rio de
Janeiro are YF free and Iguaçu has a very low YF
endemicity [8], the correct approach according to
Swiss recommendations would be to abstain from
YFV, in both vaccine availability scenarios. As
YFV is not mandatory for a trip to Brazil, an ex-
emption certificate is unnecessary.
Around 60% of respondents decided not to im-
munise in both scenarios; still more than a third
opted for an unneeded exemption. Although not
harmful, it brings along additional costs for the
traveller as well as unnecessary workload.
4. As Cameroon has a moderate YF endemicity [8],
Swiss recommendations would rather favour YFV
in this pregnant woman regardless of vaccine
availability depending on her destination within
Cameroon. However, this decision might be argu-
able.
Around 40% of specialists decided to vaccinate in
both scenarios. A larger group opted for an exemp-
tion. Still, in case of sufficient vaccine supplies,
5% chose not to vaccinate without handing out an
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exemption. This decision may cause problems, as
YFV is mandatory for entering Cameroon.
5. The traveller is not exposed to YF during this trip,
but Thailand requires YFV when entry occurs
within 10 days after visiting an endemic country.
In the case of sufficient vaccine supplies, YFV is
recommended; otherwise an exemption should be
issued.
More than 90% correctly decided to vaccinate the
traveller in scenario (i); in scenario (ii), half of the
respondents correctly opted for an exemption. In
both scenarios, some specialists decided neither to
vaccinate nor to exempt, leaving the traveller at
risk of not being able to enter Thailand.
6. YFV is contraindicated under azathioprine/
6–mercaptopurine [9]. Also, issuing an exemption
is not recommended owing to the high YF infec-
tion risk; hence, this trip should not be undertaken.
In both scenarios, around 70% would have issued
an exemption. However, it is alarming that more
than 20% decided to vaccinate endangering the im-
munosuppressed traveller due to the replication ca-
pacity of the attenuated vaccine strain. A minority
would have not vaccinated without issuing an ex-
emption.
7. According to 2013 WHO recommendations, a
single YFV dose provides lifelong protection [7],
even if a person started immunosuppressive med-
ication afterwards. Therefore, an exemption should
be issued to enter Ethiopia, as YFV is mandatory
coming from an YF endemic country.
A majority chose the correct answer; however,
more than a quarter decided not to issue an ex-
emption despite Ethiopian regulations. In scenario
(i), 10% of experts would have given YFV even
though it is clearly contraindicated under immun-
osuppression [9].
8. This traveller is still protected from the vaccine
dose he received in 1973 according to WHO re-
commendations [7]. According to entry regula-
tions, neither vaccination nor exemption is neces-
sary if entering Kenya directly from Europe.
Around 20% responded to vaccinate the traveller
in scenario (i), although unnecessary by new WHO
recommendations [7].
In our survey, delay or cancellation of a trip or interrupting
immunosuppressive medication was not an option;
however, in real life this will sometimes (but not always!)
be a solution, as was also indicated by several comments
on the questionnaires.
Overall, we saw that even among experts in a country with
one of the highest travel frequencies, great uncertainty ex-
ists regarding the indication for YFV. Partly, these dis-
agreements or uncertainties are provoked by the new WHO
recommendations as well as conflicting border regulations.
The Strategic Advisory Group of Experts on Immunization
of the WHO stated in May 2013 that a single YFV dose
confers lifelong protection (opposed to the previous
10-year recommendation). This decision is still viewed
with scepticism among experts [10, 11] as studies looking
at long-term immunity after YFV show conflicting results
(table 1 in Ref. [12]). Furthermore, many countries have
not adapted their border policies consistently. Thus, travel
health practitioners find themselves in a conflicting situ-
ation between current WHO recommendations and official
country regulations, further complicated by constantly
changing country-specific entry requirements. Currently, if
in doubt, YFV is often administered rather than risking
the traveller being denied entry into a country. However, it
is assumed that all countries will respect the new recom-
mendations of lifelong protection after YFV in due time.
Table 1: Case descriptions and results from the yellow fever vaccination survey among Swiss tropical and travel health experts.
Sufficient yellow fever vaccine available Yellow fever vaccine shortage
Overall
n
Vaccinate
n (%)
Not vaccinate
n (%)
Exemption
n (%)
Overall
n
Vaccinate
n (%)
Not vaccinate
n (%)
Exemption
n (%)
Cases 1 and 2: Couple travelling to South-East Zambia and returning to Switzerland via South Africa. While the 62-year-old wife flies back directly (transiting only in
Johannesburg), her 63-year-old husband stays for three more days in Johannesburg. Both never vaccinated against YF.
Wife 38 14 (36.8) 23 (60.5) 1 (2.6) 34 2 (5.9) 20 (58.8) 12 (35.3)
Husband 40 35 (87.5) 3 (7.5) 2 (5.0) 34 7 (20.6) 4 (11.8) 23 (67.7)
Case 3: 27-year-old woman, 15th week of pregnancy, travelling to Rio, São Paolo and for 3 days to Iguaçu. Never vaccinated against YF.
43 2 (4.7) 26 (60.5) 15 (34.9) 33 1 (3.0) 20 (60.6) 12 (36.4)
Case 4: 31-year-old woman, 23rd week of pregnancy, travelling to Cameroon. Never vaccinated against YF.
40 17 (42.5) 2 (5.0) 21 (52.5) 33 13 (39.4) – 20 (60.6)
Case 5: 35-year-old man, travelling three weeks to Peru (Lima, Cuzco, Machu Picchu) and Bolivia (La Paz, Cochabamba), then directly for 2 weeks to Thailand. Never
vaccinated against YF.
42 38 (90.5) 2 (4.8) 2 (4.8) 38 14 (36.8) 5 (13.2) 19 (50.0)
Case 6: 30-year-old woman, travelling three weeks to Ghana for scientific studies with fieldwork. She suffers from Crohn's disease and is treated with azathioprine/
6–mercaptopurine. Never vaccinated against YF.
39 8 (20.5) 4 (10.3) 27 (69.2) 31 7 (22.6) 1 (3.2) 23 (74.2)
Case 7: 59-year-old man, travelling to Uganda and Ethiopia for three weeks. Because of a polycythaemia he is treated with the cytostatic agent hydroxicarbamide.
Received a documented YF vaccination in 1999.
42 4 (9.5) 12 (28.6) 26 (61.9) 34 2 (5.9) 9 (26.5) 23 (67.7)
Case 8: 65-year-old man, travelling to Kenya for a visit to the Maasai Mara National Reserve. Received a documented YF vaccination in 1973.
43 8 (18.6) 34 (79.1) 1 (2.3) 35 1 (2.9) 31 (88.6) 3 (8.6)
YF = yellow fever
Swiss travel vaccination recommendations of October 2013 [1] are in bold type.
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